Twenty common errors in the diagnosis and treatment of periprosthetic joint infection

Cheng Li 1 · Nora Renz 1 · Andrej Trampuz 1 · Cristina Ojeda-Thies 2

Received: 16 July 2019 / Accepted: 23 September 2019 / Published online: 22 October 2019
© The Author(s) 2019

Abstract
Background Misconceptions and errors in the management of periprosthetic joint infection (PJI) can compromise the treatment success. The goal of this paper is to systematically describe twenty common mistakes in the diagnosis and management of PJI, to help surgeons avoid these pitfalls.

Materials and methods Common diagnostic and treatment errors are described, analyzed and interpreted.

Results Diagnostic errors include the use of serum inflammatory biomarkers (such as C-reactive protein) to rule out PJI, incomplete evaluation of joint aspirate, and suboptimal microbiological procedures (such as using swabs or collection of insufficient number of periprosthetic samples). Further errors are missing possible sources of distant infection in hematogenous PJI or overreliance on suboptimal diagnostic criteria which can hinder or delay the diagnosis of PJI or mislabel infections as aseptic failure. Insufficient surgical treatment or inadequate antibiotic treatment are further reasons for treatment failure and emergence of antimicrobial resistance. Finally, wrong surgical indication, both underdebridement and overdebridement or failure to individualize treatment can jeopardize surgical results.

Conclusion Multidisciplinary teamwork with infectious disease specialists and microbiologists in collaboration with orthopedic surgeons have a synergistic effect on the management of PJI. An awareness of the possible pitfalls can improve diagnosis and treatment results.

Keywords Periprosthetic joint infection · Synovial fluid analysis · Hip arthroplasty · Knee arthroplasty · Joint replacement surgery

Introduction
Prosthetic joint infection (PJI) is a serious complication of joint replacement surgery, requiring extended periods of hospitalization and re-operations and posing a significant financial burden. PJI has been found to be the most common cause of failure after hip arthroplasty [1] and of early failure after knee replacement [2]. In spite of increased interest and advances in the diagnosis and management of PJI [3–7], it remains a challenge for the treating physicians, and recent meta-analyses have reported microbiological failure rates of 0–40% for one- and two-stage revision for infected hip and knee arthroplasties [8–12]. Failure can be due to patient factors, microbiological factors [13], or factors related to errors during diagnosis and treatment [14, 15]. The goal of this article is to provide a summary of the possible pitfalls and errors during the process of diagnosing and treating PJI.

Diagnostic errors in PJI

Delayed diagnosis
Infection should be ruled out in any patient with persistent wound leakage, or a warm, swollen, or painful joint. Unfortunately, it is common to minimize the problem, taking a “wait and see” approach, losing valuable time, as the effectiveness of debridement, antibiotics, and implant retention (DAIR) decreases as surgical delay increases [16]. Bacteria adhere on implants within seconds and start surrounding...
themselves by a self-produced extracellular polysaccharide matrix; mature biofilm with the more difficult-to-eradicate sessile bacteria can be found at approximately three weeks [17, 18].

Use of swab samples

Microbiological culture samples from tissue swabs should be avoided. Previous reports have shown that the sensitivity of swab culture is low (53–76%) and is often associated with misidentification of causative pathogens [19]. Results of swab-based samples from draining wounds or sinus tracts are misleading, as they are likely to produce polymicrobial or false-positive results due to contamination with skin flora such as coagulase-negative staphylococci and Cutibacterium spp. The concordance with deep tissue samples is low (53%) [20].

Use of serum C-reactive protein and erythrocyte sedimentation rate to rule out infection

Surgeons frequently report using C-reactive protein (CRP) and erythrocyte sedimentation rates (ESRs) as first-line tests in suspected PJI, because of their convenience and short waiting times. They are strongly recommended in the 2010 guidelines of the American Association of Orthopaedic Surgeons (AAOS) [21, 22]. However, CRP and ESR are inflammatory markers with a low sensitivity: levels within the normal range do not rule out infection. Pérez-Prieto et al. [23] found that one third of PJI presented normal CRP levels and that approximately two thirds of these also had a normal ESR, and Akgün et al. [24] had similar findings. This is the case especially in low-grade infections due to coagulase-negative staphylococci and Cutibacterium spp. [25] or in patients under antibiotic treatment [26]. Though elevated ESR and/or CRP levels were included as a diagnostic criterion in the 2011 definition of PJI by the Musculoskeletal Infection Society (MSIS) [27] and the 2013 guidelines of the Infectious Diseases Society of America (IDSA) [4], the 2018 Proceedings of International Consensus Meeting (ICM) on Orthopedic Infections underlined that negative test results do not exclude the possibility of infection [28].

Disregarding distant sources of infection

Haematogenous spread from a distant infectious focus onto the prosthesis through filtration of bacteria during bacteremia is the second most common pathogenesis after peri-operative contamination. Persistent sources of infection should be considered if inflammatory biomarker levels do not fall steadily after initiating PJI treatment or when symptoms present acutely after a prolonged pain-free period following initial implantation. Primary infectious foci can be identified in the majority of acute haematogenous infections [29]. Common sources are the cardiovascular system, skin and soft tissue, oral cavity, and urogenital and gastrointestinal tracts (Fig. 1).

Incomplete synovial fluid analysis

Arthrocentesis is the most commonly performed pre-operative invasive test for suspected PJI. However, in a survey among European surgeons, many focused merely on synovial fluid culture, with one in four ignoring the diagnostic value of aspirate leukocyte count and polymorphonuclear cell (PMN) percentage [21]. However, synovial fluid culture has been found to have a relatively low sensitivity and specificity [30], and over reliance on identifying a micro-organism pre-operatively in the synovial fluid can miss cases of PJI. In addition, knowing the causal micro-organism pre-operatively—or not—does not compromise reinfection rates after treatment [31]. A recent meta-analysis of ten studies found that synovial fluid white blood cell (WBC) count had a sensitivity of 90.0% (95% confidence interval (CI) 87.2–92.2%) and a specificity of 89.8% (95% CI 81.4–94.7%), though with differences when regarding total hip and total knee arthroplasties and when considering different thresholds [32, 33]. The threshold of \( \geq 1700 \text{ WBC/mm}^3 \) recommended in the 2010 AAOS guidelines [22] and the 2013 IDSA guidelines [4] had a higher sensitivity but lower specificity than the \( \geq 3000 \text{ WBC/mm}^3 \) suggested in the 2018 ICM Proceedings [28]. Synovial WBC count and PMN percentages are unable to detect pathogens but can help discern true-positive and false-positive results. Furthermore, PMN percentage is not affected by antibiotic treatment [34]. Synovial fluid cell count may,
however, be increased in patients with rheumatic arthritis, in patients with periprosthetic fractures, and in the early post-operative period following joint replacement, with false-positive results more likely in these settings [34, 35]. Other diagnostic tests have been popularized in the last decade such as alpha defensin. Predominantly in low-grade infections, the sensitivity of this biomarker and synovial polymerase chain reaction (PCR), but their diagnostic performance has been found to be inferior to conventional diagnostic methods, with several authors recommending their use as a confirmatory tool in equivocal cases rather than as a screening tool [35, 36]. Molecular tests such as synovial PCR did not outperform conventional culture in general, except in infections caused by low-virulent pathogens [37, 38]. The clinical value of next generation sequencing (NGS) in the diagnosis of culture-negative PJI is currently investigated.

Misinterpretation of macroscopic purulence as infection in the presence of metal-on-metal bearings

Alijanpour et al. [39] found that the presence of purulence was poorly associated with isolation of a micro-organism from culture; its diagnostic accuracy was 77%. However, several guidelines include the presence of purulence in the joint as a definite criterion for the diagnosis of periprosthetic joint infection, providing that metal-on-metal (MoM) bearings were excluded [3, 4, 27]. In MoM bearings, hypersensitivity reaction and aseptic inflammation can also generate purulent appearance (“pseudo-purulence”), along with joint pain, increased serum CRP, and other symptoms of suspected infection [40]. The fluid and tissue analyses in MoM bearings show highly increased levels of cobalt and chromium [41], including in patients with “trunniasis,” where corrosion and debris occur in the taper-stem junction of modular hip prostheses [42].

Inadequate number of periprosthetic tissue samples for bacterial culture

The most commonly used intra-operative diagnostic method is tissue sampling for culture. The IDSA recommends submitting at least three and optimally five or six periprosthetic intra-operative tissue samples for aerobic and anaerobic culture [4]. Peel et al. [43] found that five or more tissue samples did not improve diagnostic accuracy, and recommended using three samples of periprosthetic tissue in blood culture bottles (BCBs) or four samples in conventional culture (Fig. 2).

Errors during retrieval of diagnostic samples

Several pitfalls during tissue sampling can increase the risk of false-positive or false-negative results. First, tissue samples should be obtained using sharp dissection, avoiding the use of electrocautery in order to limit false-positive results due to thermal artifacts in histopathologic analysis [44, 45]. Second, samples should be retrieved from the areas where signs of infection are more pronounced and from different areas of the surgical field (e.g., in hip revisions, from the bottom of the acetabulum and from the femoral canal) [15]. Third, surgical instruments should be changed for each tissue sample to avoid a risk of cross-contamination between samples, which could impact culture results [46]. Fourth, sonication of the removed implants in polyethylene bags increases the risk of microbial contamination leading to a false-positive result [47]. Finally, when transferring synovial fluid into an EDTA tube, thorough immediate hand mixing is necessary to avoid coagulation of the sample, as this would influence the synovial WBC [48].

Overdependence on diagnostic criteria

All guidelines on PJI should be considered auxiliary tools for physicians diagnosing infection; a few cases of PJI may be missed, or cases of aseptic loosening may be mistakenly diagnosed as PJI, as the sensitivity and specificity of the diagnostic criteria proposed by scientific societies do not reach 100%, and the percentage of patients diagnosed with PJI within a patient cohort varies considerably depending on the diagnostic criteria used (Fig. 3) [35, 49, 50].

Treatment errors in PJI

Conservative treatment with antibiotics in early infections

Antibiotic treatment is commonly initiated in cases of fever, chills, persistent inflammation, or wound drainage following joint arthroplasty surgery. It is difficult to differentiate superficial wound infection from early post-operative prosthetic joint infection, and wound issues are a risk factor for PJI [51, 52]. Long-term antibiotic therapy with the intent of limiting inflammation and improving clinical symptoms without prior revision surgery has not been found to eradicate infection. As stated above, delayed surgery compromises the likelihood of success of treatment. Prompt surgery followed by antibiotic therapy is the cornerstone of successful treatment of PJI. Suppressive antibiotic therapy has limited clinical efficacy and is associated with a substantial risk of adverse effects and should be reserved for patients in whom further surgical treatment is unadvisable (i.e., extreme frailty, comorbidities) [53].
Antibiotic treatment prior to microbiological diagnosis

Corollary of the aforementioned point, the diagnostic accuracy of synovial fluid culture results is compromised if synovial fluid aspiration is performed after initiating antibiotic therapy, increasing the risk of false-negative results. The same is true for perioperative tissue cultures, and preoperative antibiotic therapy is the most important cause of culture-negative PJIs [52]. If diagnostic measures are planned in a patient currently being under antimicrobial treatment, antibiotics should be withheld for two weeks prior to microbiological sampling. Nevertheless, culture of sonicate fluid could improve the diagnostic accuracy of patients under antimicrobial treatment [47, 54].

Failure to individualize treatment

Treatment of an infected prosthesis should be tailored to the type of infection (early/acute or late/chronic infection), the causative micro-organism, the quality of the soft tissue envelope, stability of the implant, surgeon experience, and ultimately host factors (comorbidities and functional status) and patient preferences [55, 56]. In acute PJI, the duration of symptoms is less than three weeks (haematogenous or contiguous infections) or four weeks (early post-operative infections); all other infections with longer duration of symptoms are defined as chronic PJI (Table 1) [6]. Implant retention using the DAIR strategy can be used in acute PJI; all mobile parts should, however, be exchanged, as patients in whom all modular components have been exchanged are shown to have higher treatment success rates [16, 57, 58]. Other requisites for success with DAIR are sufficient debridement, infection due microorganisms sensitive to biofilm-active antibiotics, a stable arthroplasty, and good soft tissue envelope. Chronic PJIs presents with a mature biofilm; thus, the prosthesis must be exchanged. This can be performed in one or two stages, depending on the causative micro-organisms, soft tissue condition, and surgeon and patient preference. While two-stage exchange of an infected prosthesis is considered the gold standard and is the dominant option in the USA, single-stage exchange is favoured in some European countries. One-stage exchange may not be an option in patients with signs of systemic sepsis, extensive comorbidities, infection with resistant organisms, culture-negative infections, and poor soft tissue coverage [59–61]. With proper selection of surgery, success rates of PJI treatment can exceed 80–90% [59].

In patients too frail or too sick for surgery that have low functional demand or who reject surgical treatment, improvement of the patient’s quality of life should be the goal of treatment, with or without the use of antibiotics. The success rate of suppressive antimicrobial therapy has been reported to be between 23 and 83% [53, 62]. In a series of six patients in stable condition and with well-fixed prostheses treated
expectantly withholding antibiotic therapy, Giacometti Ceroni et al. [63] reported that 83.3% of patients were pain-free and without systemic symptoms after a mean follow-up of 6.7 years (range 2–10 years).

**Arthroscopic lavage for treatment of PJI**

Arthroscopic lavage of an infected prosthetic joint does not allow access to all parts of the joint, particularly the posterior part of the knee joint and the polyethylene liner backside in knee as well as other joints. In addition, it does not allow for exchange of mobile parts, reflecting insufficient debridement as mentioned above (error 12). In prosthetic hip joints, debridement is insufficient without dislocation of the femoral head, which is difficult to perform without arthrotomy. Byren et al. [64] observed four times higher failure rate following arthroscopic lavage than standard DAIR surgery. Hyman et al. [65] described favorable results in a series of eight patients with late acute hip PJIs—all patients were, however, managed with chronic antibiotic suppression in addition to arthroscopic lavage. Arthroscopy has a limited role in the diagnostic workup of a painful prosthesis, allowing for inspection of the components in search of instability and wear, exclusion of non-infectious causes, visualization of the synovium, and retrieval of samples for microbiology and histology in selected cases [14, 66–68]. Importantly, arthroscopy is an invasive intervention, which is associated with a small risk of infection; therefore, the indication for diagnostic arthroscopy should be considered carefully.

**Insufficient debridement or incomplete exchange of implants**

A common reason for treatment failure is inadequate debridement. All diseased or devitalized tissue and bone should be removed during surgery. This includes old scar tissue, sinus tracts, osteolytic regions, sequestra, and any devitalized tissue until bleeding margins are obtained. In infections with mature biofilm, all foreign material including cerclages and bone cement should be rigorously removed. Although some series have documented partial exchange of implants with acceptable results, particularly in cases in which a prosthetic component is so well-fixed that its removal could result in significant bone loss and compromise of fixation at the time of the later prosthesis reimplantation and the causative organisms are not multidrug-resistant, in immunocompetent patients without sinus tracts, this option should be the exception rather than the norm [15, 66, 69, 70], and surgeons should be aware that this could compromise treatment success.

**High-pressure pulse lavage during surgery**

Pulse lavage is commonly used in PJI surgery. In the clinical setting, the success rate in treating orthopaedic implant-related infections is similar when using high-pressure and low-pressure pulsatile lavages (81.6% vs. 84.4%, respectively; $p = 1.00$) [71]. Several in vitro studies have shown, however, that pulse lavage may not be suitable for PJI surgery, especially in cases of DAIR. Not only is pulse lavage ineffective in removing biofilms from the implant surface [72], it can also potentially increase soft tissue damage and propagate bacteria deeper into soft tissue, leading to increased bacterial retention [73].

**Errors using antibiotic-loaded cement spacers**

The use of antibiotic-loaded bone cement (ALBC) spacers in two-stage revisions has two goals: first, it provides local delivery of high doses of antibiotics, above the minimal inhibitory concentration (MIC) normally attainable locally with systemic treatment without adverse effects. Second, it serves as a filler of dead space, limiting the presence of void-filling
haematoma, avoiding joint contractures, and increasing joint stability and even mobility [74]. The drug chosen for the mixture has to meet the following requirements: (1) it needs to be thermostable enough to still be effective after the exothermic reaction of polymethyl methacrylate (PMMA) polymerization, (2) it should not interfere with the polymerization process (i.e., impede hardening of PMMA), (3) it has to be able to elute from the bone cement after hardening, (4) it has to be hydrosoluble to diffuse into the surrounding tissues, and (5) it has to be available in powder form, as adding liquid antibiotics to the cement mixture significantly decreases its mechanical strength. Many premixed ALBC mixtures are commercially available; most, however, have relatively low doses of antibiotics and are primarily intended for fixation use in reimplantation surgery in two-stage exchanges or for primary arthroplasties in high-risk patients. Furthermore, hand-mixed ALBC allows for individual tailoring of the spacer to the causative micro-organism (Table 2). Common pitfalls are using antibiotics inadequate for mixing with bone cement or that are not effective for the type of micro-organism treated (e.g., vancomycin for gram-negative bacteria). Antibiotics elute from ALBC in a negatively exponential fashion, with high doses in the first post-operative days and a loss of therapeutic levels after days to weeks, depending on the type and dose of antibiotic and cement used. Thus, the risk of the spacer acting as a foreign body at risk for biofilm formation increases as time passes. Tan et al. [75] found that the risk of reinfection increased as the spacer was left implanted for longer periods, with a clear inflection above 100 days.

“Antibiotic holiday” and joint aspiration before re-implantation in two-stage exchange surgery

Currently, there is insufficient evidence to support ceasing antibiotic treatment before reimplantation to confirm eradication of infection (Fig. 4). The duration of an antibiotic holiday seems to be less related with reinfection than the time the antibiotic cement

| Situation | Antimicrobial | Fixation cement (prophylactic dose: per 40 g PMMA cement) | Spacer cement (therapeutic dose: per 40 g PMMA cement) |
|-----------|---------------|----------------------------------------------------------|--------------------------------------------------|
| Standard situation | Gentamicin + Clindamycin | 1 g | 1 g |
| Special situations | | | |
| Staphylococcus spp. (oxacillin-/methicillin-resistant) | Gentamicin + Vancocycin or Daptomycin | 0.5 g 2 g | 0.5 g 2 g (+ 2 g³) |
| Vancomycin-resistant enterococci (VRE) | Gentamicin + Linezolid or Daptomycin or Fosfomycin sodiumᵇ | 0.5 g 1 g 2 g | 0.5–1 g 2 g 3 g |
| Resistant gram-negative pathogens (e.g., E. coli, Klebsiella, Enterobacter, Pseudomonas spp.) | Gentamicin + Colistinʰ or Fosfomycin sodiumᵇ or Meropenem or Ciprofloxacin | 0.5 g 2 g 2 g 2 g | 0.5–1 g 2 g 3 gᵈ 3 g |
| Yeasts (Candida spp.) or molds (e.g., Aspergillus spp.) | Gentamicin + Liposomal amphotericin B (Ambisome®) or Voriconazole | 0.5 g 0.2 g 0.2 g | 0.5–1 g 0.2 gʰ 0.4 gʰ |

*These Atb concentrations do not fulfill the mechanical ISO requirements for fixation cement

ᵇ Fosfomycin sodium is preferred over fosfomycin calcium due to better mechanical properties of PMMA

ᶜ Available as colistin sodium or colistin sulfate (equal efficacy)

ᵈ Improved efficacy and antimicrobial release in combination with gentamicin 1 g and clindamycin 1 g

ᵉ The literature is still controversial regarding minimal effective concentrations
spacer is implanted [75]. Joint aspiration before reimplantation is not recommended, as synovial markers do not correlate with reinfection rates, and the diagnostic accuracy is very low (sensitivity of 4.6% and 25.0% and specificity of 94.3% and 96.9% for synovial fluid and cell count, respectively) [75–77]. To date, there is no reliable marker to prove the eradication of infection at the time of reimplantation. In a recent study, the outcome of PJI treatment remained high despite omission of the antibiotic-free interval before re-implantation [78].

**Errors in the selection of antibiotic treatment**

Antibiotic treatment should be based on the type of microorganism, drug susceptibility, and the type of surgery performed (Table 3). Not all antibiotics are equally active against sessile bacteria embedded in biofilm (examples of biofilm active antibiotics are rifampicin for several gram-positive pathogens (e.g., *Staphylococcus* species, *Cutibacterium* species) and ciprofloxacin for gram-negative rods), and these should be reserved for the period after implantation of the definitive implant (Fig. 4). In two-stage exchanges, we do not recommend using the antibiotics in the prosthesis-free interval but rather initiate them once the prosthesis has been re-implanted. In one-stage exchanges and infections treated with DAIR, biofilm-active therapy should be initiated post-operatively as soon as the wounds are dry and drains removed [6]. Another error is prescribing oral antibiotics with bad bone penetration and poor oral bioavailability, resulting in insufficient local concentrations at the site of infection (e.g., beta-lactam antibiotics). Furthermore, single-drug regimens such as rifampin monotherapy should be avoided in order to minimize the risk of selecting drug-resistant micro-organisms [59].

**Inadequate management of soft tissues**

Occasionally, there are difficulties for adequate closure of the soft tissue envelope surrounding a joint arthroplasty. A plastic surgeon should be consulted promptly, because any exposed prosthesis will quickly be colonized with micro-organisms and covered in biofilm. Wound revision, with revision of the prosthesis if necessary, is always indicated, as it is the only way to guarantee a favourable course, both from the infectious and from the functional point of view. Negative pressure wound therapy should not be used, as it can lead to superinfection with gram-negative or multiresistant micro-organisms [79]; if inevitable, its use should be limited in time, only as a short bridging therapy of a few days before the plastic surgeon can perform definite coverage with local or free flaps [14, 15, 55].

**Lack of specialized multidisciplinary teamwork**

The diagnosis and treatment of PJI involves multiple steps, including but not limited to the evaluation of the patient, particularly the affected joint, the interpretation of synovial fluid analysis and bacterial culture results, the development and execution of the surgical plan, and the choice of antibiotic treatment. This involves at least microbiologists, infectious disease specialists, and orthopaedic and plastic surgeons. The orthopedic surgeon should not choose the antibiotic cocktail alone, as choosing the right regimen is difficult. It is essential that the surgeon works very closely with an infectious disease specialist experienced in the treatment of implant infections. Conversely, the infectious disease specialist should not propose surgical treatments without understanding their impact and their importance to the patient and without knowing the different techniques employed by the surgeon. A microbiologist can assist in both the correct retrieval
Table 3  Targeted antibiotic therapy regimens

| Micro-organism (bold-italics: difficult-to-treat) | Antibiotic\(^a\) (check pathogen susceptibility before) | Dose\(^b\) (italics: renal adjustment needed) | Route |
|-------------------------------------------------|------------------------------------------------------|---------------------------------------------|-------|
| **Staphylococcus spp.**                         |                                                      |                                             |       |
| Oxacillin-/methicillin-susceptible               | Flucloxacillin\(^c\)                                  | 4 × 2 g                                     | i.v.  |
|                                                | (± Fosfomycin)                                       | (3 × 5 g)                                   | i.v.  |
|                                                | For 2 weeks, followed by (according to susceptibility) |                                             |       |
|                                                | Rifampicind\(^d\) +                                  | 2 × 450 mg                                  | p.o.  |
|                                                | Levofoxacin or                                       | 2 × 500 mg                                  | p.o.  |
|                                                | Cotrimoxazole or                                     | 3 × 960 mg                                  | p.o.  |
|                                                | Doxycyclin or                                        | 2 × 100 mg                                  | p.o.  |
|                                                | Fusidic acid                                         | 3 × 500 mg                                  | p.o.  |
| Oxacillin-/methicillin-resistant                 | Daptomycin or                                       | 1 × 8 mg/kg                                 | i.v.  |
|                                                | Vancomycin\(^f\)                                     | 2 × 1 g                                     | i.v.  |
|                                                | (± Fosfomycin)                                       | (3 × 5 g)                                   | i.v.  |
|                                                | For 2 weeks, followed by an oral rifampin combination as above |
| **Rifampicin-resistant**                        | Intravenous treatment according susceptibility for 2 weeks (as above), followed by long-term suppression for ≥ 1 year |
| **Streptococcus spp.**                          | Penicillin G\(^g\) or                                | 4 × 5 million U                             | i.v.  |
|                                                | Ceftriaxone                                          | 1 × 2 g                                     | i.v.  |
|                                                | For 2–4 weeks, followed by                           |                                             |       |
|                                                | Amoxicillin                                          | 3 × 1000 mg                                 | p.o.  |
|                                                | Doxycycline                                          | 2 × 100 mg                                  | p.o.  |
| (Consider suppression for 1 year)               |                                                      |                                             |       |
| **Enterococcus spp.**                           | Amoxicillin +                                        | 4 × 2 g                                     | i.v.  |
| Penicillin-susceptible                          | Gentamicin\(^f\)                                     | 1 × 120 mg                                  | i.v.  |
|                                                | (± Fosfomycin)                                       | (3 × 5 g)                                   | i.v.  |
|                                                | For 2–3 weeks, followed by                           |                                             |       |
|                                                | Amoxicillin                                          | 3 × 1000 mg                                 | p.o.  |
| **Penicillin-resistant**                        | Vancomycin\(^f\)                                     | 2 × 1 g                                     | i.v.  |
|                                                | Daptomycin +                                        | 1 × 10 mg/kg                                | i.v.  |
|                                                | Gentamicin\(^f\)                                     | 1 × 120 mg                                  | i.v.  |
|                                                | (± Fosfomycin)                                       | (3 × 5 g)                                   | i.v.  |
|                                                | For 2–4 weeks, followed by                           |                                             |       |
|                                                | Linezolid (max. 4 weeks)                             | 2 × 600 mg                                  | p.o.  |
| **Vancomycin-resistant (VRE)**                  | Individual; removal of the implant or lifelong suppression necessary, e.g., with doxycycline (if susceptible) |
| Gram-negative                                   |                                                      |                                             |       |
| **Enterobacteriaceae**                          | Ciprofloxacin\(^g\)                                  | 2 × 750 mg                                  | p.o.  |
| (E. coli, Klebsiella, Enterobacter, etc.)       |                                                      |                                             |       |
| **Non-fermenters (Pseudomonas aeruginosa, Acinetobacter spp.)** | Piperacillin/tazobactam or                          | 3 × 4.5 g                                   | i.v.  |
|                                                | Meropenem or                                         | 3 × 1 g                                     | i.v.  |
|                                                | Ceftazidime +                                       | 3 × 2 g                                     | i.v.  |
|                                                | Tobramycin                                          | 1 × 300 mg                                  | i.v.  |
|                                                | (or gentamicin)                                      | 1 × 240 mg                                  | i.v.  |
|                                                | For 2–3 weeks, followed by                           |                                             |       |
|                                                | Ciprofloxacin                                        | 2 × 750 mg                                  | p.o.  |
| **Ciprofloxacin-resistant**                    | Depending on susceptibility: meropenem 3 × 1 g, colistin 3 × 3 million U, and/or fosfomycin 3 × 5 g i.v., followed by oral suppression |
| Anaerobes                                       | Penicillin G\(^g\) or                                | 4 × 5 million U                             | i.v.  |
of samples and the processing of these in order to provide an exact diagnosis. Though, to our knowledge, no study has evaluated multidisciplinary interventions in a randomized manner [80], several authors have shown that a multidisciplinary protocol provides excellent results, with a lower length of in-hospital stay, number of surgeries, and number of antibiotics required [14, 31, 55, 81–84].

Conclusions

Management of prosthetic joint infections is a challenge, and there are many possible sources of errors in the diagnosis and treatment of these patients. A thorough understanding of the biology of these infections and the advantages and limitations of existing diagnostic tests and surgical options is essential. Awareness of the potential pitfalls and a systematic approach can improve the likelihood of success.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Jafari SM, Coyle C, Mortazavi SMJ et al (2010) Revision hip arthroplasty: infection is the most common cause of failure. Clin Orthop Relat Res 468:2046–2051. https://doi.org/10.1007/s11999-010-1251-6
2. Thiele K, Perka C, Matziolis G et al (2015) Current failure mechanisms after knee arthroplasty have changed: polyethylene wear is less common in revision surgery. J Bone Joint Surg Am 97:715–720. https://doi.org/10.2106/JBJS.M.01534
3. Parvizi J, Gehrke T, Mont MA, Callaghan JJ (2019) Introduction: proceedings of International Consensus on Orthopedic Infections. J Arthroplast 34:S1–S2. https://doi.org/10.1016/j.arth.2018.09.038
4. Osmon DR, Berbari EF, Berendt AR et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1–e25. https://doi.org/10.1093/cid/cis803
5. Arvieux C, Common H (2019) New diagnostic tools for prosthetic joint infection. Orthop Traumatol Surg Rep 105:S23–S30. https://doi.org/10.1016/j.otsr.2018.04.029
6. Li C, Renz N, Trampuz A (2018) Management of periprosthetic joint infection. Hip Pelvis 30:138–146. https://doi.org/10.5371/hp.2018.30.3.138
7. Li C, Renz N, Thies CO, Trampuz A (2018) Meta-analysis of sonicate fluid in blood culture bottles for diagnosing periprosthetic joint infection. J Bone Jt Infect 3:273–279. https://doi.org/10.7150/jbji.29731
8. Leonard HAC, Liddle AD, Burke O et al (2014) Single- or two-stage revision for infected total hip arthroplasty? A systematic review of the literature. Clin Orthop Relat Res 472:1036–1042. https://doi.org/10.1007/s11999-013-2944-y
9. Masters JPM, Smith NA, Foguet P et al (2013) A systematic review of the evidence for single stage and two stage revision of infected knee replacement. BMC Musculoskelet Disord 14:222. https://doi.org/10.1186/1471-2474-14-222
10. Nagra NS, Hamilton TW, Ganatra S et al (2016) One-stage versus two-stage arthroplasty for infected total knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc 24:3106–3114. https://doi.org/10.1007/s00167-015-3780-8
11. Yaghmour KM, Chisari E, Khan WS (2019) Single-stage revision surgery in infected total knee arthroplasty: a PRISMA systematic review. J Clin Med 8. https://doi.org/10.3390/jcm8020174
12. Kunutsor SK, Whitehouse MR, Lenguerrand E, et al (2016) Re-infection outcomes following one- and two-stage surgical revision of infected knee prosthesis: a systematic review and meta-analysis. PLoS One 11. https://doi.org/10.1371/journal.pone.0151537
13. Fagotti L, Tatka J, Salles MJC, Queiroz MC (2018) Risk factors and treatment options for failure of a two-stage exchange. Curr Rev Musculoskelet Med 11:420–427. https://doi.org/10.1007/s12178-018-9504-1
14. Borens O, Tissot C, Delaloye J-R, Trampuz A (2012) Ten errors to avoid while dealing with infected total joint arthroplasties. Rev Med Suisse 8:2452–2456
15. Kocjančič B, Dolinar D (2014) The most common surgical errors in the treatment of prosthetic joint infections. Zdravniški Vestnik 83:544–554
16. Tsang S-TJ, Ting J, Simpson AHRW, Gaston P (2017) Outcomes following debridement, antibiotics and implant retention in the management of periprosthetic infections of the hip: a review of cohort studies. Bone Joint J 99-B:1458–1466. https://doi.org/10.1302/0301-620X.99B11.BJJ-2017-0088.R1
17. Gbjejuade HO, Lovering AM, Webb JC (2015) The role of microbial biofilms in prosthetic joint infections. Acta Orthop 86:147–158. https://doi.org/10.1109/17453674.2014.966290
18. Zimmerli W, Sendi P (2017) Orthopaedic biofilm infections. APMIS 125:353–364. https://doi.org/10.1111/apm.12687
19. Aggarwal VK, Higuera C, Deirmengian G et al (2013) Swab cultures are not as effective as tissue cultures for diagnosis of periprosthetic joint infection. Clin Orthop Relat Res 471:3196–3203. https://doi.org/10.1007/s11999-013-2974-y
20. Tetreault MW, Weters NG, Aggarwal VK et al (2013) Should draining wounds and sinususes associated with hip and knee arthroplasties be cultured? J Arthroplast 28:133–136. https://doi.org/10.1016/j.arth.2013.04.057
21. Ahmad SS, Becker R, Chen AF, Kohl S (2016) EKA survey: diagnosis of prosthetic knee joint infection. Knee Surg Sports Traumatol Arthrosc 24:3050–3055. https://doi.org/10.1007/s00167-016-4303-y
22. Delta Valle C, Parvizi J, Bauer TW et al (2011) American Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis of periprosthetic joint infections of the hip and knee. J Bone Joint Surg Am 93:1355–1357. https://doi.org/10.2106/JBJS.9314eb0
23. Pérez-Prieto D, Portillo ME, Puig-Verdú L et al (2017) C-reactive protein may misdiagnose prosthetic joint infections, particularly chronic and low-grade infections. Int Orthop 41:1315–1319. https://doi.org/10.1007/s00264-017-3430-5
24. Akgün D, Müller M, Perka C, Winkler T (2018) The serum level of C-reactive protein alone cannot be used for the diagnosis of prosthetic joint infections, especially in those caused by organisms of low virulence. Bone Joint J 100-B:1482–1486. https://doi.org/10.1302/0301-620X.100B11.BJJ-2018-0514.R1
25. Renz N, Mudrovic S, Perka C, Trampuz A (2018) Orthopedic implant-associated infections caused by Cutibacterium spp.—a remaining diagnostic challenge. PLoS One 13:e0202639. https://doi.org/10.1371/journal.pone.0202639
26. Shahi A, Deirmengian C, Higuera C et al (2015) Premature therapeutic antimicrobial treatments can compromise the diagnosis of late periprosthetic joint infection. Clin Orthop Relat Res 473:2244–2249. https://doi.org/10.1007/s11999-015-4142-z
27. Parvizi J, Zmistowski B, Berbari EF et al (2011) New definition for periprosthetic joint infection: from the Workgroup of the Musculoskeletal Infection Society. Clin Orthop Relat Res 469:2992–2994. https://doi.org/10.1007/s11999-011-2102-9
28. Bauer TW, Bedair H, Creech JD et al (2019) Hip and knee section, diagnosis, laboratory tests: proceedings of International Consensus on Orthopedic Infections. J Arthroplast 34:S351–S359. https://doi.org/10.1016/j.arth.2018.09.019
29. Rakow A, Perka C, Trampuz A, Renz N (2018) Origin and characteristics of haematogenous periprosthetic joint infection. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.10.010
30. Fernández-Sampredo M, Farías-Álvarez C, Garces-Zarralejo C, et al (2017) Accuracy of different diagnostic tests for early, delayed and late prosthetic joint infection. BMC Infect Dis 17. https://doi.org/10.1186/s12879-017-2693-1
31. Karcewski D, Winkler T, Perka C, Müller M (2018, 2018) The preoperative microbial detection is no prerequisite for the indication of septic revision in cases of suspected periprosthetic joint infection. Biomed Res Int. https://doi.org/10.1155/2018/1729605
32. De Fino M, Giavaresi G, Fini M et al (2018) The role of synovial fluid analysis in the detection of periprosthetic hip and knee infections: a systematic review and meta-analysis. Int Orthop 42:983–994. https://doi.org/10.1007/s00264-018-3865-3
33. Zahar A, Laussmann C, Cavalheiro C et al (2018) How reliable is the cell count analysis in the diagnosis of prosthetic joint infection? J Arthroplast 33:3257–3262. https://doi.org/10.1016/j.arth.2018.05.018
34. Trampuz A, Hanssen AD, Osmun DR et al (2004) Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee
infection. Am J Med 117:556–562. https://doi.org/10.1016/j.ajmed.2004.06.022

35. Renz N, Yermak K, Perka C, Trampuz A (2018) Alpha defensin lateral flow test for diagnosis of periprosthetic joint infection: not a screening but a confirmatory test. J Bone Joint Surg Am 100:742–750. https://doi.org/10.2106/JBJS.17.01005

36. Kelly MP, Darrith B, Hannon CP et al (2018) Synovial fluid alpha-defensin is an adjunctive tool in the equivocal diagnosis of periprosthetic joint infection. J Arthroplasty 33:3537–3540. https://doi.org/10.1016/j.arth.2018.06.026

37. Suda AJ, Tinelli M, Beissmann ND et al (2017) Diagnosis of periprosthetic joint infection using alpha-defensin test or multiplex-PCR: ideal diagnostic test still not found. Int Orthop 41:1307–1313. https://doi.org/10.1007/s00264-017-4312-7

38. Morgenstern C, Cabric S, Perka C et al (2018) Synovial fluid multiplex PCR is superior to culture for detection of low-virulent pathogens causing periprosthetic joint infection. Diagn Microbiol Infect Dis 90:115–119. https://doi.org/10.1016/j.diagmicrobio.2017.10.016

39. Alijanipour P, Adeli B, Hansen EN et al (2015) Intraoperative puncture is not reliable for diagnosing periprosthetic joint infection. J Arthroplasty 30:1403–1406. https://doi.org/10.1016/j.arth.2015.03.005

40. Biant LC, Bruce WJM, van der Wall H, Walsh WR (2010) Infection or allergy in the painful metal-on-metal total hip arthroplasty? J Arthroplasty 25:334.e11–334.e16. https://doi.org/10.1016/j.arth.2008.08.015

41. Rakow A, Schoon J, Dienelt A et al (2016) Influence of particulate and dissociated metal-on-metal hip endoprostheses wear on mesenchymal stromal cells in vivo and in vitro. Biomaterials 98:31–40. https://doi.org/10.1016/j.biomaterials.2016.04.023

42. Koper MC, Mathijsen NMC, Witt F et al (2016) Clinical and wear analyses of 9 large metal-on-metal total hip prostheses. PLoS One 11:e0163438. https://doi.org/10.1371/journal.pone.0163438

43. Peel TN, Spelman T, Dylla BL et al (2017)Optimal periprosthetic tissue specimen number for diagnosis of prosthetic joint infection. J Clin Microbiol 55:234–243. https://doi.org/10.1128/JCM.01914-16

44. Zmistowski B, Della Valle C, Bauer TW et al (2014) Diagnosis of periprosthetic joint infection. J Arthroplasty 29:77–83. https://doi.org/10.1016/j.arth.2013.09.040

45. Parvizi J, Fasshihi SC, Enayatollahi MA (2016) Diagnosis of periprosthetic joint infection following hip and knee arthroplasty. Orthop Clin North Am 47:505–515. https://doi.org/10.1016/j.jocl.2016.03.001

46. Makki D, Abdalla S, El Gamal T et al (2018) Is it necessary to change instruments between sampling sites when taking multiple tissue specimens in musculoskeletal infections? Ann R Coll Surg Engl 100:563–565. https://doi.org/10.1308/rcsann.2018.0007

47. Trampuz A, Piper KE, Hanssen AD et al (2006) Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination. J Clin Microbiol 44:628–631. https://doi.org/10.1128/JCM.44.2.628-631.2006

48. Ochsner PE, Borens O, Bodler P-M, Schweizerische Gesellschaft für Orthopädie und Traumatologie (2014) Infections of the musculoskeletal system: basic principles, prevention, diagnosis and treatment

49. Sigmund IK, Yermak K, Perka C et al (2018) Is the enzyme-linked immunosorbent assay more accurate than the lateral flow alpha defensin test for diagnosing periprosthetic joint infection? Clin Orthop Relat Res 476:1645–1654. https://doi.org/10.1097/CORR.0000000000003336

50. Parvizi J, Tan TL, Goswami K et al (2018) The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. J Arthroplasty 33:1309–1314.e2. https://doi.org/10.1016/j.arth.2018.02.078

51. Segreti J, Parvizi J, Berbari E et al (2017) Introduction to the Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee guideline for prevention of surgical site infection: prosthetic joint arthroplasty section. Surg Infect 18:394–400. https://doi.org/10.1089/surg.2017.068

52. Johnson DP, Bannister GC (1986) The outcome of infected arthroplasty of the knee. J Bone Joint Surg (Br) 68:289–291

53. Tsukayama DT, Wicklund B, Gustilo RB (1991) Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics 14:841–844

54. Trampuz A, Piper KE, Jacobson MJ et al (2007) Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 357:654–663. https://doi.org/10.1056/NEJMoa061588

55. Baker RP, Furustrand Tafin U, Borens O (2015) Patient-adapted treatment for prosthetic joint infection. Hip Int 25:316–322. https://doi.org/10.1016/j.hipint.2015.05.016

56. Ozkoc iova P, Borens O, Trampuz A (2019) Periprosthetic joint infection: current concepts and outlook. EFOF Open Rev 4:482–494. https://doi.org/10.13052/2058-5241.4.180092

57. Zhang C, Yan CH, Chan PK et al (2017) Polyethylene insert exchange is crucial in debridement for acute periprosthetic infections following total knee arthroplasty. J Knee Surg 30:36–41. https://doi.org/10.1055/s-0036-1579667

58. Choi H-R, von Knoch F, Zurakowski D et al (2011) Can implant retention be recommended for treatment of infected TKA? Clin Orthop Relat Res 469:961–969. https://doi.org/10.1007/s11999-010-1679-8

59. Zimmerli W (2014) Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med 276:111–119. https://doi.org/10.1111/joim.12233

60. Renner L, Perka C, Trampuz A, Renz N (2016) Treatment of periprosthetic infections. Chirurg 87:831–838. https://doi.org/10.1007/s00104-016-0255-5

61. Bialecki J, Bucci S, Fernando N et al (2019) Hip and knee section, treatment, one stage exchange: proceedings of International Consensus on Orthopedic Infections. J Arthroplasty 34:S421–S426. https://doi.org/10.1016/j.arth.2018.09.026

62. Segreti J, Nelson JA, Trenholm GA (1998) Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 27:711–713. https://doi.org/10.1086/514951

63. Giacometti Ceroni R, Bianchi L, Mondini A, Zagra L (2012) Periprosthetic infections. When to avoid surgery. Hip Int 22(Suppl 8):S75–S78. https://doi.org/10.5011/HIP.2012.9574

64. Byren I, Bejon P, Atkins BL et al (2009) One hundred and twelve infected arthroplasties treated with “DAIR” (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 63:1264–1271. https://doi.org/10.1093/jac/dkp107

65. Hyman JL, Salvati EA, Laurenenc CT et al (1999) The arthroscopic drainage, irrigation, and débridement of late, acute total hip arthroplasty infections: average 6-year follow-up. J Arthroplasty 14:903–910

66. Abouljoud MM, Backstein D, Battenberg A et al (2019) Hip and knee section, treatment, surgical technique: proceedings of International Consensus on Orthopedic Infections. J Arthroplasty 34:S445–S451. https://doi.org/10.1016/j.arth.2018.09.029

67. Pohl F, Mühlföhrer HML, Lenze U et al (2017) Diagnostic accuracy of arthroscopic biopsy in periprosthetic infections of the hip. Eur J Med Res 22:6. https://doi.org/10.1186/s40001-017-0246-0

68. Claassen L, Ettinger S, Pastor M-F et al (2016) The value of arthroscopic neosynovium biopsies to diagnose periprosthetic knee joint low-grade infection. Arch Orthop Trauma Surg 136:1753–1759. https://doi.org/10.1007/s00402-016-2574-x
69. Anagnostakos K, Meyer C (2019) Partial two-stage exchange at the site of periprosthetic hip joint infections. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-019-03180-0

70. El-Husseiny M, Haddad FS (2016) The role of highly selective implant retention in the infected hip arthroplasty. Clin Orthop Relat Res 474:2157–2163. https://doi.org/10.1007/s11999-016-4936-7

71. Muñoz-Mahamud E, García S, Bori G et al (2011) Comparison of a low-pressure and a high-pressure pulsatile lavage during débridement for orthopaedic implant infection. Arch Orthop Trauma Surg 131:1233–1238. https://doi.org/10.1007/s00402-011-1291-8

72. Urich KL, DeMuth PW, Craft DW et al (2014) Pulse lavage is inadequate at removal of biofilm from the surface of total knee arthroplasty materials. J Arthroplast 29:1128–1132. https://doi.org/10.1016/j.arth.2013.12.012

73. Hassinger SM, Harding G, Wongworawat MD (2005) High-pressure pulsatile lavage propagates bacteria into soft tissue. Clin Orthop Relat Res 439:27–31. https://doi.org/10.1097/01.blo.0000182246.37454.b2

74. Soares D, Leite P, Barreira P et al (2015) Antibiotic-loaded bone cement in total joint arthroplasty. Acta Orthop Belg 81:184–190

75. Tan TL, Kheir MM, Rondon AJ et al (2018) Determining the role and duration of the “antibiotic holiday” period in periprosthetic joint infection. J Arthroplast 33:2976–2980. https://doi.org/10.1016/j.arth.2018.04.019

76. Preininger B, Janz V, von Roth P et al (2017) Inadequacy of joint aspiration for detection of persistent periprosthetic infection during two-stage septic revision knee surgery. Orthopedics 40:231–234. https://doi.org/10.3928/01477447-20170411-04

77. Boelch SP, Weissenger M, Spohn F et al (2018) Insufficient sensitivity of joint aspiration during the two-stage exchange of the hip with spacers. J Orthop Surg Res 13. https://doi.org/10.1186/s13018-017-0703-z

78. Winkler T, Stuhlert MGW, Lieb E et al (2019) Outcome of short versus long interval in two-stage exchange for periprosthetic joint infection: a prospective cohort study. Arch Orthop Trauma Surg 139:295–303. https://doi.org/10.1007/s00402-018-3052-4

79. Yusuf E, Jordan X, Clauss M et al (2013) High bacterial load in negative pressure wound therapy (NPWT) foams used in the treatment of chronic wounds. Wound Repair Regen 21:677–681. https://doi.org/10.1111/wrr.12088

80. Abblitt WP, Ascione T, Bini S et al (2019) Hip and knee section, outcomes: proceedings of International Consensus on Orthopedic Infections. J Arthroplast 34:S487–S495. https://doi.org/10.1016/j.arth.2018.09.035

81. Ibrahim MS, Raja S, Khan MA, Haddad FS (2014) A multidisciplinary team approach to two-stage revision for the infected hip replacement: a minimum five-year follow-up study. Bone Joint J 96-B:1312–1318. https://doi.org/10.1302/0301-620X.96B10.32875

82. Laurent E, Lemaignen A, Gras G et al (2019) Multidisciplinary team meeting for complex bone and joint infections diagnosis: the PHICTOS study. Rev Epidemiol Sante Publique 67:149–154. https://doi.org/10.1016/j.respe.2019.01.121

83. Ntalos D, Berger-Groch J, Rohde H et al (2019) Implementation of a multidisciplinary infections conference affects the treatment plan in prosthetic joint infections of the hip: a retrospective study. Arch Orthop Trauma Surg 139:467–473. https://doi.org/10.1007/s00402-018-3079-6

84. Yan CH, Arciola CR, Soriano A et al (2018) Team approach: the management of infection after total knee replacement. JBJS Rev 6: e9. https://doi.org/10.2106/JBJS.RVW.17.00058

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.